A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera) and Tocilizumab (RoActemra) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Rituximab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 18 Mar 2013 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov record.
- 11 Mar 2013 Planned end date changed from 1 May 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.